Vivior and SwissLens establish collaboration for the development of personalized contact lenses
Both Swiss companies agreed to collaborate in the field of personalized multifocal soft contact lenses for presbyopia correction. The objective is to optimize the design in soft multifocal contact lenses by using the data generated by Vivior’s visual behavior monitor, the Vivior Monitor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191202005453/en/
“The cooperation with SwissLens represents another milestone for Vivior. With SwissLens we have an established Swiss company as a partner in the growing field of multifocal personalized contact lenses. Both cooperation partners pursue the goal of achieving better vision comfort for customers and patients and complement each other perfectly in terms of technology,” says Andreas Kelch, Sales & Marketing Manager Vision Care at Vivior.
“With Vivior's innovative monitoring system, we obtain objective measurement data of visual behavior that are still unknown today. As a manufacturer of individual lenses, we can incorporate this data into the development of innovative new multifocal lenses. We are pleased about the partnership and the possibly resulting optimized lens designs that should enable the wearer to see better in all areas of vision,” explains Pascal Blaser, Head of Sales and R&D leader at SwissLens.
About SwissLens
Since 1997, SwissLens in Prilly, near Lausanne (Switzerland), has been manufacturing individual contact lenses of the highest quality and distributing them to eye specialists in over 25 countries. Thanks to extensive research, patented and innovative manufacturing technologies, SwissLens is constantly developing its products and services.
About Vivior
Vivior is a Swiss digital health start-up founded in 2017 by a group of experienced eye care professionals. The company offers a novel wearable device – the Vivior Monitor – to objectively measure visual behavior prior to vision correction interventions. The system collects daily activity data from customers and patients, processes these data in the cloud, and analyzes the lifestyle patterns using machine-learning algorithms. This ground-breaking combination allows to understand better the needs of customers and patients and enables eye care professionals to offer optimal personalized solutions to them. In addition, Vivior develops personalized spectacle, contact and intraocular lenses for vision correction in collaboration with various partners. The goal is to achieve better vision comfort for customers and patients based on the data generated by the Vivior Monitor.
www.vivior.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005453/en/
Contact information
For more information, please contact:
Vivior AG
Mario Stark, CEO
mario.stark@vivior.com
+41 79 542 88 74
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 16:00:00 EEST | Press release
As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. Taking place on October 15, 2025, at the iconic Shangri-La at The Shard in London, Elevate'25 moves beyond the headlines to provide a practical roadmap for success, featuring insights from brand executives and industry-defining keynotes. "Unprecedented advancements in AI and mobile-first consumer behaviors are driving a seismic shift that is reshaping how brands interact with customers now and far into the future,” sa
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime18.9.2025 16:00:00 EEST | Press release
Lenovo research reveals a widening security gap as AI-driven cybercrime surges: 65% of IT leaders surveyed admit their defenses are outdated and unable to withstand AI-enabled attacks, and just 31% feel confident defending against them. The new insights are drawn from Lenovo’s third Work Reborn report, Reinforcing the Modern Workplace. While AI is driving business improvements and efficiency gains, it is also fueling a new wave of cybercrime that most businesses are ill-equipped to defend against. This underscores the critical need for enterprises to adopt AI-driven strategies that can counter threats that learn, adapt, and evolve in real time. Lenovo is positioned to deliver this shift with end-to-end solutions that embed AI security into the digital workplace. With operations in 180 markets and a leader in enterprise technology, Lenovo brings unmatched scale to solving AI workplace challenges, from protecting sensitive data to countering evolving cyber threats. “AI has changed the ba
Armis Receives Morgan Stanley 2025 Innovation Award18.9.2025 16:00:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has received the prestigious Innovation Award from Morgan Stanley at the Firm’s 23rd Tech Week event in Silicon Valley. For over 20 years, Morgan Stanley has celebrated companies with innovative capabilities that have materially impacted its business. Armis is being recognized for its partnership with Morgan Stanley, which chose Armis to help protect and secure its critical internet-of-things (IoT) assets across its organization. “Continuous and cutting-edge innovation that enables global cybersecurity teams to combat malicious actors is essential in today’s environment. The attack surface is growing exponentially, and Armis’ mission is to protect organizations’ entire attack surface by managing cyber risk exposure in real time,” said Yevgeny Dibrov, Armis Co-founder and CEO. “We are honored by our partnership with Morgan Stanley and look forward to supporting their continued efforts to actively manage and
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 15:33:00 EEST | Press release
Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 15:30:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformative treatment provides to patients, families and the health care system.” In Italy, there are approximately 5,000 people 12 years and older living with TDT and around 2,300 with SCD. Italy joins a number of countries that have signed reimbursem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom